Ownership
Private
Stage
Other
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
AntibodyRecombinant proteinCell therapyGene therapyVaccine (biologic)

Automated Engineering Services General Information

Automated Engineering Services (AES) is an active global engineering and automation solutions provider specializing in supporting biopharmaceutical and biomanufacturing companies. They offer end-to-end support from R&D to commercial manufacturing through advanced lab integration, custom OEM equipment design, process automation, data management, staffing services, and aftermarket support. Their technologies enable production of antibodies/recombinant proteins, cell therapies, gene therapies, vaccines, cultured foods, and industrial biotech products. AES does not develop drugs but empowers clients to accelerate development/manufacturing of life-saving treatments[1][4][5].

Contact Information

Primary Industry
Drug Discovery Services
Corporate Office
,
United States

Drug Pipeline

No pipeline data available

For full access to Automated Engineering Services's pipeline data

Book a demo

Key Partnerships

Not specified publicly—likely partners with major biopharma manufacturers as clients but no named partnerships disclosed[1][4].

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Automated Engineering Services Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Automated Engineering Services's complete valuation and funding history, request access »

Automated Engineering Services Financial Metrics